Vanderbilt Ingram Cancer Center

Displaying 1 - 10 of 17


Colorectal cancer researchers receive SPORE funding

Colorectal cancer researchers from Vanderbilt-Ingram Cancer Center (VICC) have been awarded a Specialized Program of Research Excellence grant from the National Cancer Institute (NCI).


Grant bolsters research on myelodysplastic syndromes

Michael Savona, MD, professor of Medicine and Cancer Biology, and director of Hematology Research at Vanderbilt- Ingram Cancer Center, has received a competitive grant award from the Edward P. Evans Foundation.

The Discovery Research Grant (DRG) will support his work to develop therapies for patients with myelodysplastic syndromes, a group of cancers that occur when immature blood cells in the bone marrow don’t fully develop or fail to become healthy blood cells.


A critical factor for wound healing

Using mouse skin as a model system, J. Scott Beeler, Jennifer Pietenpol, PhD, and colleagues found that p73 is required for the timely healing of cutaneous wounds. In normal tissue, p73 expression increased in response to wounding, whereas p73 deficiency resulted in delayed wound healing, they reported in the journal PLOS ONE.


Encephalitis identified as rare toxicity of immunotherapy treatment

After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center (VICC) investigated why the complication occurred, performing a molecular analysis of the disease’s pathology and mining data to determine the incidence of similar occurrences.


Discovery points to new cancer immunotherapy option

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.


Investigators map genomic landscape of very rare cancer

A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.


Research explores link between stem cell transplant, diabetes

About a decade ago, at the beginning of his career in academic medicine, Brian Engelhardt, MD, MSCI, noticed that many of his patients receiving a stem cell transplant for their blood cancer ended up with diabetes.